HOME >> BIOLOGY >> NEWS
The HIV Nef protein plays both offense and defense in the battle between the AIDS virus and the body's immune system

In fighting the body's immune system, HIV owes part of its success to its ability to destroy those cells normally recruited to mount the body's counter-attack against the HIV-infected cells. Lying at the crux of such success is a viral protein called Nef, which protects its infected host while simultaneously destroying the neighboring uninfected cells of the immune system, according to scientists at the Gladstone Institute of Virology and Immunology.

"It's HIV going both ways, playing offense and defense," said Warner C. Greene, MD, PhD, director of the Gladstone Institute of Virology and Immunology and UCSF professor in the departments of medicine and microbiology and immunology. "It is a rather remarkable example of the cunning strategy the AIDS virus employs to help ensure its survival and spread."

Researchers have long known that cells surrounding an HIV-infected cell are eliminated by way of a programmed self-destructive process known as apoptosis. And Nef, the researchers knew, somehow plays a key role in triggering this destruction. Now in a study published in the April 12, 2001 issue of Nature, Gladstone scientists have discovered that Nef also protects its infected host cell from the detrimental effects by using the same trigger. The new study shows that Nef does this by binding to and inhibiting a protein called ASK1, a key player in apoptosis.

"If we could effectively block the assembly of Nef and ASK1, it could lead to the premature death of the HIV-infected host cell," Greene said. "The HIV infection process would then be short-circuited and the virus might simply die out because it would not have sufficient time to fully reproduce itself."

Achieving such a block will require discovering and developing a molecule that interrupts the assembly of Nef and ASK1, helping to "tip the balance in favor of the body effectively dealing with the virus," he said.

Identifying such a molecule could lead to the develop
'"/>

Contact: Laura Lane
llane@gladstone.ucsf.edu
415-476-2557
University of California - San Francisco
10-Apr-2001


Page: 1 2

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. Researchers identify protein promoting vascular tumor growth
3. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
4. Experimental drug shown to block mutant protein causing blood disease
5. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
6. Images of tail of protein needed for cell multiplication suggest anticancer drug targets
7. New dye directly reveals activated proteins in living cells
8. Disruption of protein-folding causes neurodegeneration, mental retardation
9. A new protein is discovered to play a key role in cancer progression
10. Optimizing proteins death domain halts leukemia in laboratory study
11. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins

Post Your Comments:
(Date:7/2/2015)... Fingerprint Cards has received an order for its ... distributor World Peace Industrial Group (WPI), part of WPG Holdings. ... . Deliveries are planned to take place during Q3 ... manufacturers in Asia . The order value ... of approximately 2,200 MSEK for 2015. Jörgen Lantto, ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
(Date:7/3/2015)... Forskare kan ansöka ... http://www.openinnovationinscience.at till det återkommande utbildningsprogrammet "Lab ... i Wien .  ... forskare och vetenskapsmän som genomfördes av Ludwig ... utmaningar bristen på incitament för att undersöka ...
(Date:7/2/2015)... GLEN ELLYN, Ill. , July 2, 2015 /PRNewswire-USNewswire/ ... and Colton Eakins are gaining invaluable real-world ... Institute of Technology this summer. The students ... Dr. Jeff Wereszczynski,s research group at IIT. ... Professors Dr. Tom Carter , Physics; Dr. ...
(Date:7/1/2015)... ... 2015 , ... It is now possible to separate two common disorders: post-traumatic ... tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas Jefferson University, and ... is believed to be the largest brain imaging study ever, will be published on ...
(Date:7/1/2015)... 2015   Neuraltus Pharmaceuticals, Inc. , a privately-held ... drugs to treat neurodegenerative diseases such as amyotrophic ... G. Miller , M.D., Director of the Forbes Norris ... Medical Center in San Francisco, has been awarded a ... to help fund a Phase 2 clinical study ...
Breaking Biology Technology:Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3COD Students Participate in Prestigious Summer Internships 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4
Cached News: